BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
65.93
-0.03 (-0.04%)
May 13, 2026, 10:12 AM EDT - Market open
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 24 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $86.96, which forecasts a 31.91% increase in the stock price over the next year. The lowest target is $49 and the highest is $130.
Price Target: $86.96 (+31.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 | 7 | 7 |
| Buy | 12 | 13 | 15 | 17 | 18 | 18 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 23 | 25 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $100 → $110 | Strong Buy | Maintains | $100 → $110 | +66.86% | May 11, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $125 → $130 | Buy | Maintains | $125 → $130 | +97.19% | May 8, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $95 → $102 | Strong Buy | Maintains | $95 → $102 | +54.72% | Apr 29, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +51.69% | Apr 29, 2026 |
| Mizuho | Mizuho | Buy Reiterates $106 | Buy | Reiterates | $106 | +60.79% | Apr 28, 2026 |
Financial Forecast
Revenue This Year
954.51M
from 502.08M
Increased by 90.11%
Revenue Next Year
1.66B
from 954.51M
Increased by 73.91%
EPS This Year
-1.98
from -3.78
EPS Next Year
0.76
from -1.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3B | 2.4B | ||||||
| Avg | 954.5M | 1.7B | ||||||
| Low | 771.1M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 159.1% | 150.5% | ||||||
| Avg | 90.1% | 73.9% | ||||||
| Low | 53.6% | 13.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.10 | 3.01 | ||||||
| Avg | -1.98 | 0.76 | ||||||
| Low | -3.20 | -1.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.